Results 41 to 50 of about 4,378 (208)

A pilocytic astrocytoma with novel ATG16L1::NTRK2 fusion responsive to larotrectinib: a case report with genomic and functional analysis. [PDF]

Oncologist
Deland L, Keane S, Olsson Bontell T, Sjöberg Bexelius T, Gudinaviciene I, De La Cuesta E, De Luca F, Nilsson JA, Carén H, Mörse H, Abel F.   +10 more
europepmc   +2 more sources

Larotrectinib Sulfate [PDF]

, 2020
National Cancer Institute
openaire   +2 more sources

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

Current Oncology, 2022
NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), ETV6-NTRK3 gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced ...
Matthew S. Ernst, John T. Lysack, Martin D. Hyrcza, Shamir P. Chandarana, Desiree Hao   +4 more
doaj   +1 more source

A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling. [PDF]

Oncologist
Thavaneswaran S, Sim HW, Grady J, Espinoza D, Huang ML, Lin F, McGrath M, Desai J, Charakidis M, Brown M, Kansara M, Simes J, Thomas D.   +12 more
europepmc   +2 more sources

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Journal of Hematology & Oncology, 2018
Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell ...
Yu Chen, Ping Chi
doaj   +1 more source

Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review

Frontiers in Oncology, 2023
Infantile fibrosarcoma (IFS) is a rare tumor in childhood characterized by a single, localized, painless mass that grows rapidly but has a relatively indolent biological behavior and a favorable prognosis.
Dandan Wang, Dandan Wang, Fanhui Zhang, Fanhui Zhang, Wanli Feng, Wanli Feng, Jiarong Pan, Jiarong Pan, Tianming Yuan, Tianming Yuan   +9 more
doaj   +1 more source

Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review)

Опухоли головы и шеи, 2020
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare salivary cancer, histologically resembling to secretory carcinoma of the breast. In 2017 World Health Organization reported MASC is a new salivary cancer subtype. The aim of this
A. V. Ignatova, A. M. Mudunov, S. О. Podvyaznikov, Yu. V. Alymov   +3 more
doaj   +1 more source

Diagnostic challenges and successful organ‐preserving therapy in a case of secretory carcinoma of minor salivary glands

Cancer Reports, 2022
Background Secretory carcinoma is a more recently described subtype of salivary gland carcinoma that may pose diagnostic challenges and frequently harbors NTRK fusions that may successfully be targeted by TRK inhibitors in advanced disease.
Ruben Bill, Daniel G. Deschler, Mikael J. Pittet, Sara I. Pai, Peter M. Sadow, Jong Chul Park   +5 more
doaj   +1 more source

Larotrectinib (Vitrakvi)

Canadian Journal of Health Technologies, 2021
CADTH recommends that Vitrakvi be reimbursed by public drug plans for treating adult and pediatric patients with locally advanced or metastatic solid tumours who have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, or where surgical resection is likely to result in severe morbidity and have no ...
openaire   +3 more sources

Larotrectinib in TRK fusion-positive, metastatic non-small cell lung cancer (NSCLC) after treatment with entrectinib in a patient with a history of coronary artery disease

Current Problems in Cancer: Case Reports, 2022
Here, we describe a patient with advanced metastatic non-small cell lung cancer (NSCLC) who harbors a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, identified by liquid biopsy, and has a known history of heart disease.
Derrick W. Su, Janet Pan, Nour Shahab, Hoang Le, Kamini Malhotra, Tushar Patel   +5 more
doaj   +1 more source